Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Serpiginous choroiditis is a rare inflammatory eye condition that typicallydevelops betweenage 30 and 70 years. Affected individuals have lesions in the eye thatlast from weeks to months and involve scarringof the eye tissue.Recurrence of these lesionsis common in serpiginous choroiditis. Vision loss may occurin one or both eyeswhen the macula is involved. Treatment options involve anti-inflammatory and immune-suppressing medications.
Biomarker and diagnostic research for serpiginous choroiditis has been reported in the published literature.
No clinical trials have been registered for serpiginous choroiditis.
29 publications have been identified in PubMed for serpiginous choroiditis. Research spans Case Report / Case Series (41%), Review / Meta-Analysis (31%), and Diagnostic / Biomarker (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 12 | 41% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 1:53 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
9 |
31% |
Testing and diagnosis research | 4 | 14% |
Disease patterns and progression | 2 | 7% |
Other research | 1 | 3% |
Clinical study results | 1 | 3% |
Trinco A (2026). [PMID: 42191103](https://pubmed.ncbi.nlm.nih.gov/42191103/). *Am J Ophthalmol*. [Diagnostic / Biomarker]
Joukainen E (2026). [PMID: 41852703](https://pubmed.ncbi.nlm.nih.gov/41852703/). *Clin Ophthalmol*. [Case Report / Case Series]
Feo A (2026). [PMID: 41490810](https://pubmed.ncbi.nlm.nih.gov/41490810/). *Am J Ophthalmol*. [Review / Meta-Analysis]
Faghihi S (2026). [PMID: 41492569](https://pubmed.ncbi.nlm.nih.gov/41492569/). *Am J Ophthalmol Case Rep*. [Case Report / Case Series]
Galvan J (2026). [PMID: 41673272](https://pubmed.ncbi.nlm.nih.gov/41673272/). *Eye (Lond)*. [Case Report / Case Series]
Bianco L (2026). [PMID: 41861897](https://pubmed.ncbi.nlm.nih.gov/41861897/). *Am J Ophthalmol*. [Review / Meta-Analysis]
Hooper CY (2026). [PMID: 40706821](https://pubmed.ncbi.nlm.nih.gov/40706821/). *Surv Ophthalmol*. [Review / Meta-Analysis]
De Simone L (2026). [PMID: 41919587](https://pubmed.ncbi.nlm.nih.gov/41919587/). *Ocul Immunol Inflamm*. [Diagnostic / Biomarker]
Boyce TM (2026). [PMID: 42063291](https://pubmed.ncbi.nlm.nih.gov/42063291/). *Ocul Immunol Inflamm*. [Epidemiology / Natural History]
Horowitz SA (2026). [PMID: 42181358](https://pubmed.ncbi.nlm.nih.gov/42181358/). *Cureus*. [Case Report / Case Series]